Moderna stock rises 8%: can it continue its cancer vaccine success rally?

Moderna (MRNA) stock continued to rise on Thursday as investors assessed positive late-stage results for the company's personalised mRNA cancer vaccine and a series of analyst upgrades and higher pric...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。